Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 22Active not recruiting 14Withdrawn 7Completed 5Terminated 3Suspended 3Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 9Standard of Care 6Educational Status 6Nivolumab 5Interviews as Topic 5Carboplatin 5Radiotherapy 4Paclitaxel 4Oxaliplatin 4Dexamethasone 4pembrolizumab 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Fluorouracil 3Fluorodeoxyglucose F18 3Exercise 3Early Intervention, Educational 3Drug Therapy 3Cytarabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2tislelizumab 2sacituzumab govitecan 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × decitabine and cedazuridine drug combination × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡